Drug intelligence / Profile preview

ER-XIE-TING

Development stage: Unknown
Lead developer: China Resources Sanjiu Medical & Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

ER-XIE-TING is a proprietary traditional Chinese medicine formulation developed for the treatment of acute diarrhea. The formulation contains Glycyrrhizae Radix et Rhizoma (licorice root), Mumefructus (smoked plum fruit), and Rabia (likely a transliteration or herbal component, but exact botanical identity unclear from available sources). Its mechanism of action is not fully elucidated in Western pharmacological terms, but it is used within the framework of Traditional Chinese Medicine to address symptoms associated with acute diarrhea. The product has been recognized as a protected traditional Chinese medicine by regulatory authorities in China.

Brand names: Er Xie Ting Ke Li
Other names: Proprietary Chinese Medicine ER-XIE-TING

Beyond the preview

Go deeper on ER-XIE-TING.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ER-XIE-TING.

Explore the full profile